Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...
Zacks.com on MSN4d
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease StudyUNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...
The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...
Australia-based Opthea, a biopharma developing therapies for progressive retinal diseases, has announced results from its ...
Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces ...
Clinical Trials Arena on MSN5d
Opthia could owe $1bn to investors amid sozinibercept trial failureThe Australian biotech could potentially be on the hook for more than $1bn after sozinibercept failed to show impact over ...
Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, ...
The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients with diabetic macular edema (DME) who had poor ...
its aflibercept biosimilar of EYLEA®. As we have previously reported, the Federal Circuit recently affirmed a similar preliminary injunction against Samsung and Formycon. In that opinion ...
Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback